Lung Cancer Liquid Biopsy Market Increasing Demand, Growth Analysis and Future Outlook by 2031

The global lung cancer liquid biopsy market is anticipated to grow at a significant CAGR of 13.4% during the forecast period (2024-2031). The increasing lung cancer incidence and growing demand for non-invasive diagnostic methods along with ongoing technological advancements is a key factor driving the growth of the global market. According to the National Library of Medicine, in January 2023, lung cancer was observed as one of the cancers with the highest incidence rate and the second-highest mortality rate in the world. Moreover, according to the American Cancer Society, lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in the US (not counting skin cancer). The American Cancer Society's estimates for lung cancer in the US for 2024 are:

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-liquid-biopsy-market

• About 234,580 new cases of lung cancer (116,310 in men and 118,270 in women)
• About 125,070 mortalities from lung cancer (65,790 in men and 59,280 in women)
In December 2022, Agilent Technologies Inc. received FDA approval for Agilent Resolution ctDx FIRST as a companion diagnostic used to identify advanced non-small lung cancer in patients. The ongoing FDA approval for instruments used in lung cancer liquid biopsy treatment is further contributing to the global market growth.

Global Lung Cancer Liquid Biopsy Market Report Segment

By Application

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring

By Biomarker

• Circulating Nucleic Acids
• CTC
• Exosomes/Microvesicles
• Circulating Proteins

By End-User

• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers

By Products

• Instruments
• Consumables Kits and Reagents
• Software and Services

A full report of Lung Cancer Liquid Biopsy Market available @ https://www.omrglobal.com/industry-reports/lung-cancer-liquid-biopsy-market

Lung Cancer Liquid Biopsy Market Report Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Exact Sciences Corp.
• Guardant Health
• Immucor
• LungLife AI, Inc.
• MDxHealth
• Menarini Silicon Biosystems
• Myriad Genetics, Inc.
• Thermo Fisher Scientific Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.


Visit more report at

https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/

https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.